CDF
Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England
August 2, 2016Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer
Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …
Roche urges reform of Cancer Drugs Fund as NICE takes control
July 29, 2016Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE, Roche
Roche has warned that cancer patients in England are facing into an “uncertain future” as the new Cancer Drugs Fund …
Eisai criticises NICE and CDF for rare cancer ‘black hole’ in England
July 8, 2016Medical Communications, Research and Development CDF, Eisai, NICE, black hole
Japanese pharmaceutical company Eisai (TYO: 4523) has issued a statement expressing its dismay that advanced thyroid cancer patients in England …
Nice rejects AstraZeneca’s Tagrisso for lung cancer in preliminary recommendation
June 24, 2016Medical Communications, Research and Development AstraZeneca, CDF, NICE, lung cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said the National Institute for Health and Care Excellence (Nice) has rejected Tagrisso (osimertinib) to …
Nice rejects Celgene’s drug to treat blood cancer
June 24, 2016Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer
The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …
Cancer Drugs Fund ‘not sustainable in current form’
September 17, 2015CDF, Cancer Drugs Fund, Department of Health, NHS England, National Audit Office, Public Accounts Committe, Roche, avastin
The Cancer Drugs Fund has improved access to treatments, although the UK still lags behind other countries despite its ‘unsustainable’ …
Companies braced for new round of cancer cuts
September 4, 2015Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, cuts
Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund …
Cancer Drugs Fund assessment to be handed over to NICE
July 22, 2015Medical Communications, Research and Development CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, NHSE, NICE, cost effectiveness, cost-effectiveness
NICE will oversee the evaluation of Cancer Drugs Fund treatments in future, under new plans due for consultation by NHS …
Sanofi prostate cancer drug to remain on CDF
May 26, 2015Sales and Marketing CDF, Cancer, NHS, Sanofi, list, prostate
Sanofi has reached an agreement with NHS England to reinstate its prostate cancer drug Jevtana on the Cancer Drugs Fund. …
Bayer wins Cancer Drugs Fund appeal
May 22, 2015Sales and Marketing Bayer, CDF, Cancer Drugs Fund, Eisai, NHS, lilly
Bayer is the only company to win its appeal to NHS England in the latest round of Cancer Drugs Fund …
NHS backtracks on Cancer Drugs Fund de-listings
March 12, 2015Sales and Marketing Afinitor, CDF, Cancer Drugs Fund, England, Halaven, NHS, Novartis, everolimus
NHS England is expected to perform a U-turn on several decisions to remove treatments from the cancer drugs fund when …
Oncologists say CDF cuts will compromise treatment
March 10, 2015Sales and Marketing CDF, Jevtana, NHS, NICE, Sanofi, cabazitaxel, doctors.net, m3
Oncologists believe cutting drugs from the Cancer Drugs Fund won’t save the NHS money and will worsen patient outcomes according …
NHS reform was ‘distracting and damaging’
February 6, 2015Sales and Marketing CDF, Cameron, NHS, UK, coalition, healthcare, king's fund
Healthcare think tank The King’s Fund has said through a report that organisational changes to the NHS under the coalition …
Half of UK population will get cancer
February 4, 2015Research and Development, Sales and Marketing CDF, CRUK, Cancer, Jevtana, Sanofi, cabazitaxel
New figures from Cancer Research UK (CRUK) suggest that one in two people will develop cancer at some point in …
Stephen Whitehead: pharma has transformed
February 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, NHS, NICE, PPRS, Stephen Whitehead, lgbt, pharma
According to The Association of the British Pharmaceutical Industry (ABPI) the dominant issue in 2015 will be the affordability and …
